title: Individualized therapy of HHT driven by network analysis of metabolomic profiles.
abstract: BACKGROUND
  Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disease with a varying range of phenotypes involving abnormal vasculature primarily manifested as arteriovenous malformations in various organs, including the nose, brain, liver, and lungs. The varied presentation and involvement of different organ systems makes the choice of potential treatment medications difficult.
  
  
  RESULTS
  A patient with a mixed-clinical presentation and presumed diagnosis of HHT, severe exertional dyspnea, and diffuse pulmonary shunting at the microscopic level presented for treatment. We sought to analyze her metabolomic plasma profile to assist with pharmacologic treatment selection. Fasting serum samples from 5 individuals (4 healthy and 1 with HHT) were metabolomically profiled. A global metabolic network reconstruction, Recon 1, was used to help guide the choice of medication via analysis of the differential metabolism between the patient and healthy controls using metabolomic data. Flux Balance Analysis highlighted changes in metabolic pathway activity, notably in nitric oxide synthase (NOS), which suggested a potential link between changes in vascular endothelial function and metabolism. This finding supported the use of an already approved medication, bevacizumab (Avastin). Following 2 months of treatment, the patient's metabolic profile shifted, becoming more similar to the control subject profiles, suggesting that the treatment was addressing at least part of the pathophysiological state.
  
  
  CONCLUSIONS
  In this 'individualized case study' of personalized medicine, we carry out untargeted metabolomic profiling of a patient and healthy controls. Rather than filtering the data down to a single value, these data are analyzed in the context of a network model of metabolism, in order to simulate the biochemical phenotypic differences between healthy and disease states; the results then guide the therapy. This presents one approach to achieving the goals of individualized medicine through Systems Biology and causal models analysis.
authors.affiliation: Department of Radiological Sciences, University of California, Los Angeles, CA, USA.
authors.forename: Neema
authors.initials: N
authors.lastname: Jamshidi
authors.forename: Franklin J
authors.initials: FJ
authors.lastname: Miller
authors.forename: Jess
authors.initials: J
authors.lastname: Mandel
authors.forename: Timothy
authors.initials: T
authors.lastname: Evans
authors.forename: Michael D
authors.initials: MD
authors.lastname: Kuo
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D016022:Case-Control Studies; D016000:Cluster Analysis; D005260:Female; D006801:Humans; D053858:Metabolic Networks and Pathways / Q000502:physiology*; D055442:Metabolome; D008954:Models, Biological; D057285:Precision Medicine / Q000379:methods*; D049490:Systems Biology / Q000379:methods*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab